Efficacy and Cost-Effectiveness of Vonoprazan–Amoxicillin Dual Therapy Versus Esomeprazole–Bismuth Quadruple Therapy for Helicobacter pylori: A Propensity Score-Matched Study
Microorganisms · 29.04.2026 · 14 (5) · 1006
DOI: 10.3390/microorganisms14051006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 29.04.2026. Verfasst von Lihua Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vonoprazan–amoxicillin (VA) dual therapy offers a simplified alternative; however, its efficacy and cost-effectiveness relative to bismuth-containing quadruple therapy (BQT) in treatment-naïve patients remain unclear. This study aimed to compare the eradication rate and cost-effectiveness between the two groups using a propensity score-matched analysis. This retrospective, single-center study used outpatient electronic medical records from January 2024 to November 2025. After propensity score matching (1:1), 212 patients received vonoprazan–amoxicillin dual therapy (VA), and 212 matched patients received esomeprazole–bismuth quadruple therapy (EBAC) for two weeks. Eradication rates and cost-effectiveness were compared. According to the intention-to-treat (ITT) analysis, eradication rates were 90.56% (95% CI 85.88–93.81%) in the VA group and 90.09% (95% CI 85.33–93.43%) in the EBAC group (p = 0.869). The per-protocol (PP) analysis showed eradication rates of 93.03% (95% CI 88.64–95.80%) and 91.58% (95% CI 86.93–94.68%), respectively (p = 0.585). Multivariate logistic regression identified non-compliance as a significant risk factor for eradication failure (OR = 5.346, 95% CI 1.847–15.473, p = 0.002). Probabilistic sensitivity analysis showed that EBAC was more cost-effective than VA in stage 1. However, the eradication rate of EBAC dramatically declined, and VA became the more cost-effective option at higher WTP thresholds in stage 2. In conclusion, the 14-day VA dual therapy is as effective as BQT therapy but is safer and easier to use, offering a more streamlined eradication option. Nonetheless, EBAC remains a cost-effective option.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.
ORCID-Profile: Lihua Guo
Zitieren
APA
Guo, L., Ge, J., Miao, M., Hu, G., Wen, J., Hu, K., & Ye, G. (2026). Efficacy and Cost-Effectiveness of Vonoprazan–Amoxicillin Dual Therapy Versus Esomeprazole–Bismuth Quadruple Therapy for Helicobacter pylori: A Propensity Score-Matched Study. Microorganisms, 14(5), 1006. https://doi.org/10.3390/microorganisms14051006
Vancouver
Guo L, Ge J, Miao M, Hu G, Wen J, Hu K, et al. Efficacy and Cost-Effectiveness of Vonoprazan–Amoxicillin Dual Therapy Versus Esomeprazole–Bismuth Quadruple Therapy for Helicobacter pylori: A Propensity Score-Matched Study. Microorganisms. 2026;14(5):1006. doi:10.3390/microorganisms14051006
BibTeX
@article{Guo2026,
author = {Guo, Lihua and Ge, Jiaxin and Miao, Min and Hu, Guimei and Wen, Jinfeng and Hu, Kefeng and Ye, Guoliang},
title = {Efficacy and Cost-Effectiveness of Vonoprazan–Amoxicillin Dual Therapy Versus Esomeprazole–Bismuth Quadruple Therapy for Helicobacter pylori: A Propensity Score-Matched Study},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {5},
pages = {1006},
doi = {10.3390/microorganisms14051006}
}
EUVIMED